A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms MEDISARC
- 04 Jun 2019 According to trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology, enrollment of patients started in April 2018.As of February 2019, 32 patients have been enrolled.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.